Enveric Biosciences, Inc. ENVB
1.50 USD +0.05 (+3.45%)
At closeNov 3, 2026, 4:02 PM EST
1.50 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
1.41 Day range 1.51
1.17 52-week range 13.25
- YTD
- -58.68%
- 1 year
- -78.81%
- Market cap
- 6.71M
- EPS (ttm)
- -13.01
- Shares out
- 9.94M
- Forward P/E
- -0.22
- YTD return
- -58.68%
- 1-year return
- -78.81%
- Volume
- 43.10K
- Avg volume
- 84.38K
- Open
- 1.45
- Previous close
- 1.45
- Day's range
- 1.41 – 1.51
- 52-week range
- 1.17 – 13.25
- Beta
- 0.47
1M -0.06 (-3.97%)
Key statistics
- Enterprise value
- -246.78K
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.43
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -9.04M
- Total cash
- 3.50M
- Total debt
- 0
- Return on equity
- -206.10%
- Short % of float
- 3.73%
- 50-day average
- 0.40876
- 200-day average
- 0.63229
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ENVB Revenue — quarterly 0
ENVB Net income — quarterly -3.03M
ENVB EPS — quarterly -0.76
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.52 | -0.24 | +0.28 | +53.85% |
| Aug 12, 2024 | Jun 1, 2024 | -0.55 | -0.25 | +0.30 | +54.55% |
| May 14, 2024 | Mar 1, 2024 | -0.61 | -0.61 | 0.00 | 0.00% |
| Mar 25, 2024 | Dec 1, 2023 | -1.55 | -1.46 | +0.09 | +5.81% |
| Nov 13, 2023 | Sep 1, 2023 | -1.93 | -1.30 | +0.63 | +32.64% |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -3.04 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 30, 2024 | HC Wainwright & Co. | init | — | Buy |
About Enveric Biosciences, Inc.
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- enveric.com
News
12 Health Care Stocks Moving In Wednesday's After-Market Session 
Enveric Biosciences Reports Favorable Preclinical Results for Non-Hallucinogenic Psychiatric Candidate 
Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies 
Enveric Biosciences Receives U.S. Patent Office Notice Of Allowance For An Application Covering Novel Compounds Within Its EVM401 Series Of Drug Candidates 
Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series 
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference 
Enveric Biosciences Q2 EPS $(0.76) Up From $(11.64) YoY 
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026 
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate 
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
Your note
Sign in to keep a note on ENVB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COVENEY KEVIN MICHAEL | Chief Financial Officer | Stock Award(Grant) | Oct 8, 2024 | 186,500 |
| DEWITT SHEILA | Director | Stock Award(Grant) | Oct 8, 2024 | 27,845 |
| FACCHINI PETER JAMES | Officer | Stock Award(Grant) | Oct 8, 2024 | 130,856 |
| HAGEL JILLIAN MARIE | Officer | Stock Award(Grant) | Jan 24, 2023 | 35,802 |
| KANUBADDI AVANI | President | Stock Award(Grant) | Jan 24, 2023 | 48,346 |
| KEGLER GEORGE A. JR | Director | Stock Award(Grant) | Oct 8, 2024 | 48,053 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 3.61% | 367,047 | 113.78K | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.14% | 217,893 | 67.55K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.30% | 30,632 | 9.49K | Sep 29, 2024 |
| Virtu Financial LLC | 0.23% | 23,117 | 7.17K | Sep 29, 2024 |
| Vanguard Group Inc | 0.18% | 18,198 | 5.64K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.17% | 17,372 | 5.38K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 6.18% | 628,307 | 194.78K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 1.61% | 163,684 | 50.74K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.42% | 42,371 | 13.13K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.18% | 18,198 | 5.64K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 10,353 | 3.21K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 463 | 143 | Oct 30, 2024 |